Structural insights into the human D1 and D2 dopamine receptor signaling complexes.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33571431.
- Also identified by DOI 10.1016/j.cell.2021.01.027 and PMC identifier 8215686.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The D1- and D2-dopamine receptors (D1R and D2R), which signal through G<sub>s</sub> and G<sub>i</sub>, respectively, represent the principal stimulatory and inhibitory dopamine receptors in the central nervous system. D1R and D2R also represent the main therapeutic targets for Parkinson's disease, schizophrenia, and many other neuropsychiatric disorders, and insight into their signaling is essential for understanding both therapeutic and side effects of dopaminergic drugs. Here, we report four cryoelectron microscopy (cryo-EM) structures of D1R-G<sub>s</sub> and D2R-G<sub>i</sub> signaling complexes with selective and non-selective dopamine agonists, including two currently used anti-Parkinson's disease drugs, apomorphine and bromocriptine. These structures, together with mutagenesis studies, reveal the conserved binding mode of dopamine agonists, the unique pocket topology underlying ligand selectivity, the conformational changes in receptor activation, and potential structural determinants for G protein-coupling selectivity. These results provide both a molecular understanding of dopamine signaling and multiple structural templates for drug design targeting the dopaminergic system.
Medical subject headings
- Receptors, Dopamine D1
- Receptors, Dopamine D2
- Signal Transduction